Track this trial free. DataLookout checks ClinicalTrials.gov daily and emails you which fields changed on NCT07793396 (status, enrollment, completion dates, endpoints, sites) when this record is updated. Free accounts track up to 5 trials.

Track this trial

Prospective Study of Eslicarbazepine in Adults With Focal-Onset Seizures

Study acronym: ENGAGE
StatusRecruiting
PhaseNot specified
Started2025-12-02
View on ClinicalTrials.gov ↗
This prospective multicenter observational study will evaluate the effectiveness, safety, tolerability, and impact on quality of life of eslicarbazepine in adults with focal-onset seizures in routine clinical practice. Participants will include newly diagnosed patients and patients previously treated with carbamazepine or oxcarbazepine who have inadequate seizure control or intolerable adverse effects. Treatment with eslicarbazepine will be initiated or changed at the discretion of the treating physician in accordance with routine clinical practice. Participants will be followed for 3 months.

Amendment record

Amended once since 2026-08-25. Every amendment is listed below.

Dates here are the day the sponsor filed the amendment, not the day ClinicalTrials.gov published it. Version history last read from ClinicalTrials.gov on 2026-09-15.

2026-09-03
Amendment Study Status, Study Description, Outcome Measures v1
2026-08-25
Original filing
Trial Details
NCT Number NCT07793396
Lead Sponsor King Edward Medical University
Conditions Focal-Onset Seizures
Enrollment 1,500 participants
Start Date 2025-12-02
Primary Completion 2026-12-31 (estimated)
Study Completion 2026-12-31 (estimated)
Updated on ClinicalTrials.gov 2026-09-09